Phaseline

Targets › OCT4

OCT4 (POU domain, class 5, transcription factor 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Ophthalmology; next expected readout May 2027.

Transcription factor that binds to the octamer motif (5'-ATTTGCAT-3'). Forms a trimeric complex with SOX2 or SOX15 on DNA and controls the expression of a number of genes involved in embryonic development such as YES1, FGF4, UTF1 and ZFP206. (UniProt, Q01860)

Open in Phaseline: the race on OCT4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Life BiosciencesER-100
AAV-based epigenetic therapy delivering OSK transcription factors (OCT4, SOX2, KLF4) via i
OCT4, SOX2, KLF4Phase 1Open Angle Glaucoma (OAG)May 2027

Conditions

Open Angle Glaucoma (OAG) (1)

Modalities

other (1)

Companies

Life Biosciences (1)

Related targets

SOX2 (1) KLF4 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.